Another hot biotech stock pick

Mannkind has developed a new type of insulin called Technosphere Insulin for diabetics. This is a big deal because it is inhaled rather than injected and in test trials its rate of hypoglycemia is far lower than other competitors. The biggest factor is most likely that it does not promote weight gain which is common for most insulin drugs out there right now. Mannkind's stock has take a hit recently with news of Pfizer narrowing in on their market share with other products, so in my opinion it's a good time to buy Mannkind.

Some more article about Mannkind if you want some background info:
From September 2007, in the New York Times
Mannkind as an overlooked biotech stock in Seeking Alpha

Pfizer rejected them back in 2007 after weak sales, but people are more confident and stronger test trials could propel them to success as a lot of people are betting. The buzz around this stock is also huge right now.